Farmácias D1000 têm queda de 24% no lucro do 3º tri…

Lucara Diamond Raises 2026 Revenue Guidance to USD 140 Million-160 Million Lucara Diamond Raises 2026 Revenue Guidance to USD 140 Million-160 Million Lucara Diamond raised L impact | EARNINGS | Nov 14, 2026, 01:10 AM UTC

Gilead Expects HIV Revenue to Grow About 12% in 2026 Gilead expects HIV revenue to grow about 12% in fiscal 2026. M impact | EARNINGS | Nov 14, 2026, 12:44 AM UTC

Asante Gold Withdraws 2026 Production and Cost Guidance Asante withdrew its 2026 guidance for 275,000–300,000 equivalent ounces at consolidated AISC of $3,200–$3,600/oz after Bibiani underperformed. Nine-month production was 165,594 equ M impact | EARNINGS | Nov 13, 2026, 11:27 PM UTC

Japan's FiEE 9M Revenue More Than Quadruples FiEE's nine-month revenue more than quadrupled, attributed to SaaS expansion. M impact | EARNINGS | Nov 13, 2026, 10:28 PM UTC

Equity Index futures dip on tech selling, hold weekly gains. Equity Index futures traded lower on Friday as technology sector weakness and rising yields weighed on markets, though major indices remained on track for weekly gains. E-mini S&P H impact | EARNINGS | Nov 13, 2026, 10:00 PM UTC

Indaptus Therapeutics Reports $5.4 Million Nine-Month Loss Indaptus Therapeutics reported a net loss of $5.4 million for the first nine months of 2026, down from $12.7 million a year earlier. Third-quarter net loss was $1.0 million versus M impact | EARNINGS | Nov 13, 2026, 09:34 PM UTC

Farmácias D1000 têm queda de 24% no lucro do 3º tri, baixam guidance de expansão

Related stories